Pfizer sues India generic drugmaker over cancer drug
14-01-2021
Delhi court approves Natco generic of Novartis cancer drug
29-08-2019
Molly Woodward / Shutterstock.com
Pfizer is seeking to block a generic version of its cancer drug Ibrance (palbociclib) from entering the market until the patent covering the drug expires in May 2036.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Pfizer, Natco, Ibrance, Palbociclib, Abbreviated New Drug Application, patent infringement, cancer drug, generic competition, US FDA
